Progenics Pharmaceuticals Inc. (PGNX)

5.70
NASDAQ : Health Technology
Prev Close 5.77
Day Low/High 5.65 / 5.99
52 Wk Low/High 5.01 / 9.42
Avg Volume 1.77M
Exchange NASDAQ
Shares Outstanding 84.54M
Market Cap 487.81M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of May 2019 Options Trading For Progenics Pharmaceuticals (PGNX)

First Week Of May 2019 Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the May 2019 expiration.

Interesting PGNX Put And Call Options For January 2021

Interesting PGNX Put And Call Options For January 2021

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the January 2021 expiration.

Buy Struggling Progenics and Dynavax Here

Buy Struggling Progenics and Dynavax Here

Both biotech stocks are at or near 52-week lows, but don't deserve to be.

RSI Alert: Progenics Pharmaceuticals (PGNX) Now Oversold

RSI Alert: Progenics Pharmaceuticals (PGNX) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Two Hundred Day Moving Average Cross - PGNX

Notable Two Hundred Day Moving Average Cross - PGNX

In trading on Monday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $7.18, changing hands as low as $7.15 per share.

Seeking Bargains on Last Week's Selloff

Seeking Bargains on Last Week's Selloff

These 5 stocks are a good value on this weakness.

Names to Watch Amid Biotech's Nascent Rally

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

3 Stocks to Consider Now

3 Stocks to Consider Now

Two things usually occur right after earnings season winds down.

Relative Strength Alert For Progenics Pharmaceuticals

Relative Strength Alert For Progenics Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week Of PGNX September 21st Options Trading

First Week Of PGNX September 21st Options Trading

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the September 21st expiration.

First Week Of February 2019 Options Trading For Progenics Pharmaceuticals (PGNX)

First Week Of February 2019 Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2019 expiration.

Strategies for 3 Biotechs Before FDA Action

Strategies for 3 Biotechs Before FDA Action

Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

First Week Of PGNX July 20th Options Trading

Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the July 20th expiration.

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

These names are moving up or down in a big way ahead of releasing drug-trial results.

4 Names to Watch Ahead of Cancer Conference

4 Names to Watch Ahead of Cancer Conference

American Society of Clinical Oncology will see presentations from dozens of companies.

4 Names to Buy in a Refreshed Biotech Space

4 Names to Buy in a Refreshed Biotech Space

After a strong week for the biotech sector, these names have potential catalysts to move shares.

Relative Strength Alert For Progenics Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Progenics Pharmaceuticals Announces Presentation Of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data At The 2018 Endocrine Society (ENDO) Annual Meeting

Progenics Pharmaceuticals Announces Presentation Of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data At The 2018 Endocrine Society (ENDO) Annual Meeting

Significant correlation between overall tumor biomarker response and achievement of the primary and secondary endpoints in pivotal study of AZEDRA

Commit To Purchase Progenics Pharmaceuticals At $6, Earn 17.4% Annualized Using Options

Commit To Purchase Progenics Pharmaceuticals At $6, Earn 17.4% Annualized Using Options

Investors eyeing a purchase of Progenics Pharmaceuticals, Inc. stock, but cautious about paying the going market price of $8.39/share, might benefit from considering selling puts among the alternative strategies at their disposal.

5 Stocks That Are Showing Signs of Reversing

5 Stocks That Are Showing Signs of Reversing

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

TheStreet Quant Rating: D (Sell)